Proof of Mechanism Study of an Oral Hedgehog Inhibitor (GDC-0449) in Patients With Resectable Pancreatic Ductal Adenocarcinoma in the Pre-operative Window Period.
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Vismodegib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Pharmacodynamics
- Acronyms HIPPoS
- 27 Jan 2014 Actual end date August 2012, added as reported by ClinicalTrials.gov record.
- 08 Sep 2012 Accrual to date is 15% according to United Kingdom Clinical Research Network record.
- 01 Sep 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.